Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Diabetes Mellitus, Type 2 2Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1

Interventions

Blood Specimen Collection 17Pancreaticoduodenectomy 15Surveys and Questionnaires 11Endoscopic Ultrasound-Guided Fine Needle Aspiration 10Observation 9Biopsy 8Specimen Handling 6Pancreatectomy 6Gemcitabine 6Data Collection 6Surgical Procedures, Operative 5Magnetic Resonance Spectroscopy 5Endosonography 5Electroporation 5Biopsy, Fine-Needle 5Neoadjuvant Therapy 4Magnetic Resonance Imaging 4Liquid Biopsy 4Interviews as Topic 4Immunologic Techniques 4Immunohistochemistry 4Drug Therapy 4folfirinox 3Fluorouracil 3Cholangiopancreatography, Endoscopic Retrograde 3Albumin-Bound Paclitaxel 3irinotecan sucrosofate 2Taxes 2Sulfonylurea Compounds 2Secretin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Pancreatic Neoplasms × Sulfonylurea Compounds × Clear all
NCT05663515 2026-05-05

EXCEED

AstraZeneca

Recruiting
24,000 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02475499 2016-03-14

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
886,172 enrolled
Gastrointestinal

Diabetes Mellitus, Type 2, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡